Overview

Nicotinic Receptors and Schizophrenia

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are non-smokers. The study drug may also maintain abstinence from cigarette smoking and improve other symptoms in patients with schizophrenia.

Phase:

Phase 2

Details

Lead Sponsor:

University of Colorado, Denver

Collaborator:

National Institute of Mental Health (NIMH)

Treatments:

3-(2,4-dimethoxybenzylidene)anabaseine